111 related articles for article (PubMed ID: 36549502)
1. Inhibiting the growth of ovarian cancer cells in vitro and in vivo by a small molecular inhibitor targeting La-RNA interactions.
Li Y; Huang X; Tang J
Eur J Pharmacol; 2023 Feb; 940():175471. PubMed ID: 36549502
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
4. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
Liu B; Huang X; Li Y; Liao W; Li M; Liu Y; He R; Feng D; Zhu R; Kurihara H
BMC Cancer; 2019 Jul; 19(1):645. PubMed ID: 31262254
[TBL] [Abstract][Full Text] [Related]
5. Berbamine suppresses cell proliferation and promotes apoptosis in ovarian cancer partially via the inhibition of Wnt/β-catenin signaling.
Zhang H; Jiao Y; Shi C; Song X; Chang Y; Ren Y; Shi X
Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):532-539. PubMed ID: 29701777
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
7. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
[TBL] [Abstract][Full Text] [Related]
8. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
9. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.
Zhang XQ; Ding YW; Chen JJ; Xiao X; Zhang W; Zhou L; Kong QW; Shi MZ; Yang J; Jiang B; Guo C; Han YL
J Ethnopharmacol; 2020 Oct; 261():113067. PubMed ID: 32505840
[TBL] [Abstract][Full Text] [Related]
10. Pyrimethamine exerts significant antitumor effects on human ovarian cancer cells both in vitro and in vivo.
Liu Y; Zhou H; Yi T; Wang H
Anticancer Drugs; 2019 Jul; 30(6):571-578. PubMed ID: 30614834
[TBL] [Abstract][Full Text] [Related]
11. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
12. A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo.
Yin Z; Mao Y; Zhang N; Su Y; Zhu J; Tong H; Zhang H
Biomed Pharmacother; 2019 Nov; 119():109420. PubMed ID: 31536932
[TBL] [Abstract][Full Text] [Related]
13. TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.
Zhong J; Kang J; Wang X; Jiang W; Liao H; Yuan J
Med Oncol; 2015 Apr; 32(4):118. PubMed ID: 25782870
[TBL] [Abstract][Full Text] [Related]
14. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway.
Liu Y; Tong L; Luo Y; Li X; Chen G; Wang Y
J Cell Biochem; 2018 Jul; 119(7):6162-6172. PubMed ID: 29663499
[TBL] [Abstract][Full Text] [Related]
16. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
17. Suppression of in vitro and in vivo human ovarian cancer growth by isoacteoside is mediated via sub-G1 cell cycle arrest, ROS generation, and modulation of AKT/PI3K/m-TOR signalling pathway.
Yang X; Guo F; Peng Q; Liu Y; Yang B
J BUON; 2019; 24(1):285-290. PubMed ID: 30941982
[TBL] [Abstract][Full Text] [Related]
18. Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGF‑β1-mediated cell cycle arrest.
Bu S; Zhang Q; Wang Q; Lai D
Int J Oncol; 2017 Nov; 51(5):1405-1414. PubMed ID: 29048644
[TBL] [Abstract][Full Text] [Related]
19. Damnacanthal isolated from morinda species inhibited ovarian cancer cell proliferation and migration through activating autophagy.
Li R; Li H; Lan J; Yang D; Lin X; Xu H; Han B; Yang M; Su B; Liu F; Jiang W
Phytomedicine; 2022 Jun; 100():154084. PubMed ID: 35421676
[TBL] [Abstract][Full Text] [Related]
20. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
